TABLE OF CONTENTS
1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.3 OVERVIEW OF GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET 28
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.8 APPLICATION GRID 40
2.9 DBMR MARKET POSITION GRID 41
2.10 VENDOR SHARE ANALYSIS 42
2.11 SECONDARY SOURCES 43
2.12 ASSUMPTION 43
3 MARKET OVERVIEW 44
3.1 DRIVERS 46
3.1.1 LARGE NUMBER OF APPROVALS FOR IODINATED AGENTS 46
3.1.2 RISING AGING POPULATION 47
3.1.3 INCREASING NUMBER OF CHRONIC DISEASES 50
3.1.4 INCREASING RESEARCH ACTIVITIES FOR CONTRAST AGENTS 51
3.2 RESTRAINTS 52
3.2.1 HIGH COST OF CONTRAST MEDIA 52
3.2.2 SIDE EFFECTS ASSOCIATED WITH CONTRAST AGENTS 52
3.3 OPPORTUNITIES 53
3.3.1 GROWING HEALTHCARE INFRASTRUCTURE 53
3.3.2 STRATEGIC INITIATIVE BY MARKET PLAYERS 54
3.3.3 GROWING NUMBER OF DIAGNOSTIC CENTERS 54
3.3.4 UPCOMING GENERIC CONTRAST MEDIA AGENTS 55
3.4 CHALLENGES 56
3.4.1 LACK OF AWARENESS REGARDING THE PROPER DOSAGE OF CONTRAST AGENT 56
3.4.2 RESTRICTION AND WITHDRAWAL OF LINEAR GADOLINIUM-BASED CONTRAST AGENTS 57
4 EXECUTIVE SUMMARY 58
5 PREMIUM INSIGHTS 61
6 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY ROUTE OF ADMINISTRATION 64
6.1 OVERVIEW 65
6.2 INTRAVENOUS 67
6.3 ORAL 68
6.4 RECTAL 68
6.5 OTHERS 69
7 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY END USER 70
7.1 OVERVIEW 71
7.2 HOSPITAL 74
7.3 SPECIALTY CLINICS 74
7.3.1 IMAGING CENTERS 75
7.3.2 PRIVATE PRACTICES 75
7.4 DIAGNOSTIC CENTERS 75
7.5 AMBULATORY SURGICAL CENTERS 75
7.6 RESEARCH & ACADEMIC INSTITUTES 76
8 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY INDICATION 77
8.1 OVERVIEW 78
8.2 CARDIOLOGY 80
8.2.1 PERCUTANEOUS CORONARY DISEASE 81
8.2.2 STRUCTURAL HEART DISEASE 81
8.2.3 CONGENITAL HEART DISEASE 81
8.2.4 ELECTROPHYSIOLOGY 81
8.3 NEUROLOGY 81
8.4 GENERAL SURGERY 82
8.5 ONCOLOGY 82
8.6 UROLOGY 83
?
9 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE 84
9.1 OVERVIEW 85
9.2 NON-IONIC 87
9.3 IONIC 88
10 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY GEOGRAPHY 89
10.1 OVERVIEW 90
10.2 NORTH AMERICA 95
10.2.1 U.S. 101
10.2.2 CANADA 104
10.2.3 MEXICO 107
10.3 EUROPE 110
10.3.1 GERMANY 116
10.3.2 U.K. 119
10.3.3 FRANCE 122
10.3.4 ITALY 125
10.3.5 SPAIN 128
10.3.6 SWITZERLAND 131
10.3.7 NETHERLANDS 134
10.3.8 RUSSIA 137
10.3.9 BELGIUM 140
10.3.10 TURKEY 143
10.3.11 REST OF EUROPE 146
10.4 ASIA-PACIFIC 147
10.4.1 CHINA 153
10.4.2 JAPAN 156
10.4.3 SOUTH KOREA 159
10.4.4 INDIA 161
10.4.5 AUSTRALIA 164
10.4.6 SINGAPORE 167
10.4.7 THAILAND 170
10.4.8 MALAYSIA 173
10.4.9 INDONESIA 176
10.4.10 PHILIPPINES 179
10.4.11 REST OF ASIA-PACIFIC 182
?
10.5 SOUTH AMERICA 183
10.5.1 BRAZIL 189
10.5.2 ARGENTINA 192
10.5.3 PERU 195
10.5.4 REST OF SOUTH AMERICA 198
10.6 MIDDLE EAST AND AFRICA 199
10.6.1 U.A.E. 205
10.6.2 SAUDI ARABIA 208
10.6.3 EGYPT 211
10.6.4 SOUTH AFRICA 214
10.6.5 ISRAEL 217
10.6.6 REST OF MIDDLE EAST & AFRICA 220
11 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, COMPANY LANDSCAPE 221
11.1 COMPANY SHARE ANALYSIS: GLOBAL 221
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 222
11.3 COMPANY SHARE ANALYSIS: EUROPE 223
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 224
12 COMPANY PROFILES 225
12.1 BRACCO DIAGNOSTIC INC. 225
12.1.1 COMPANY SNAPSHOT 225
12.1.2 COMPANY SHARE ANALYSIS 225
12.1.3 PRODUCT PORTFOLIO 225
12.1.4 RECENT DEVELOPMENT 226
12.2 GENERAL ELECTRIC 227
12.2.1 COMPANY SNAPSHOT 227
12.2.2 REVENUE ANALYSIS 228
12.2.3 COMPANY SHARE ANALYSIS 228
12.2.4 PRODUCT PORTFOLIO 229
12.2.5 RECENT DEVELOPMENTS 229
12.3 GUERBET 230
12.3.1 COMPANY SNAPSHOT 230
12.3.2 REVENUE ANALYSIS 230
12.3.3 COMPANY SHARE ANALYSIS 231
12.3.4 PRODUCT PORTFOLIO 231
12.3.5 RECENT DEVELOPMENT 231
?
12.4 BAYER AG 232
12.4.1 COMPANY SNAPSHOT 232
12.4.2 REVENUE ANALYSIS 232
12.4.3 PRODUCT PORTFOLIO 233
12.4.4 RECENT DEVELOPMENT 233
12.5 IMAX 234
12.5.1 COMPANY SNAPSHOT 234
12.5.2 PRODUCT PORTFOLIO 234
12.5.3 RECENT DEVELOPMENT 234
12.6 ISO-TEX DIAGNOSTICS, INC. 235
12.6.1 COMPANY SNAPSHOT 235
12.6.2 PRODUCT PORTFOLIO 235
12.6.3 RECENT DEVELOPMENT 235
12.7 J.B.CHEMICALS AND PHARMACEUTICALS LTD. 236
12.7.1 COMPANY SNAPSHOT 236
12.7.2 REVENUE ANALYSIS 236
12.7.3 PRODUCT PORTFOLIO 237
12.7.4 RECENT DEVELOPMENT 237
12.8 NOVALEK PHARMACEUTICALS PVT. LTD. 238
12.8.1 COMPANY SNAPSHOT 238
12.8.2 PRODUCT PORTFOLIO 238
12.8.3 RECENT DEVELOPMENT 238
12.9 TAEJOON PHARM 239
12.9.1 COMPANY SNAPSHOT 239
12.9.2 PRODUCT PORTFOLIO 239
12.9.3 RECENT DEVELOPMENT 239
12.10 UNIJULES LIFE SCIENCES LTD. 240
12.10.1 COMPANY SNAPSHOT 240
12.10.2 PRODUCT PORTFOLIO 240
12.10.3 RECENT DEVELOPMENT 240
13 QUESTIONNAIRE 241
14 RELATED REPORTS 243